In recent years, immune checkpoint proteins in the tumor microenvironment have been under intense study. If you work in the immuno-oncology field, chances are you are either performing multiplex IHC (mIHC) or would like to. Ultimately, a multiplexed image like the one featured here provides a multi-layered depiction of a tumor, such that each antibody corresponds to a different fluorescent signal. If you want to detect more targets in your IHC, but aren’t sure how to design a panel of antibodies and fluorophores for mIHC, we’ll walk you through the process in this post.
Earlier this week, Dr. James Allison and Dr. Tasuku Honjo were announced as joint winners of the 2018 Nobel Prize in Physiology or Medicine for their work in the field of immunotherapy and checkpoint immune regulation. Their studies have sparked decades of clinical advances, and changed the future of cancer therapy. A webinar presented by Dr. Allison in conjunction with Dr. Gordon Freeman and Dr. Philip Gotwals is featured in this week's blog post.
Researchers who run a lot of chromatin immunoprecipitation "ChIP" assays – maybe even your advisor – might subscribe to the idea that polyclonal antibodies perform better than monoclonal antibodies. But is that always actually true?
It’s worth your time to understand the differences between the two in terms of antigen recognition and specificity, and dispel some myths.
Research trends in macrophage plasticity
It’s an exciting time for immuno-oncology research, as potential predictive biomarkers from an expanding collection of cell types are being pursued. Explore the plasticity of tumor-associated macrophages (TAMs) and challenges in distinguishing M1- versus M2- functional states in this 5-minute video featuring CST Developmental Scientist Sarah Klein, PhD.
Can't see the embedded video? Click here to watch.
Science is science, even if it's examining totally different aspects of nature like stem cell niches versus marine habitat niches. As a company grounded in science, CST values the efforts of non-profit organizations in our community that are working to protect our ecosystems.
So you've set the timer to five minutes for the first of three TBST washes for your western blot membrane. Now what? Sure, you could check your email or social media for the 30th time before lunch. Or you could do something informative, like check out a CST Tech Tips video! This is a new short video series featuring the same scientists who develop and validate CST antibodies, here to offer insights and protocol tips.
I’m a Product Scientist at Cell Signaling Technology (CST). My typical work day no longer looks like my fellow scientists’ daily grind, and at times, I even find it difficult to describe in words what I do, but I’ll give it a shot!
Tamar Aprahamian is an interesting study in the professional opportunities available for young scientists. She's worked in academia, industry, and most recently, founded a company of science writers called JetPub. She has been a contributor to our blog and was nice enough to share her story.
Each summer, college and high school interns at CST get a chance to sample work life in a biotech environment. They are typically in the early stages of considering potential career paths, so what better time to set up a Q&A panel? Five CST employees shared some of their career development experiences during a recent “lunch and learn” session with the interns. Selections from the session have been transcribed and edited for brevity. –ed.
Q: Which do you like better, being on the bench or managing?
Topics: Career Development
Multiple myeloma (MM) is a type of hematopoietic malignancy characterized, in part, by bone pain, anemia, kidney failure, and recurring infections. The underlying mechanism that drives the disease is abnormal proliferation and accumulation of malignant plasma cells in the bone marrow that secrete large amounts of abnormal antibodies.